SCHEMBL387738

SCHEMBL387738

COc1cccc2c1[C@]1(C)CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CS2

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 1/20 0.36
CETP P11597 6/20 0.36
ALOX15 P16050 3/20 0.36
ALOX12 P18054 3/20 0.36
ENTPD5 O75356 1/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CG P48736 2/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
LTB4R Q15722 1/20 0.34
KIF11 P52732 2/20 0.33
PTGS2 P35354 1/20 0.33
GPR84 Q9NQS5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101120 0.84 PIK3CB (0.40) PIK3CBCETPALOX15ALOX12ENTPD5
SCHEMBL10101125 0.84 PIK3CB (0.38) PIK3CBCETPALOX15ALOX12ENTPD5
SCHEMBL10101150 0.83 PIK3CB (0.45) PIK3CBCETPENTPD5PIK3CAPIK3CG
SCHEMBL10101130 0.83 PIK3CB (0.41) PIK3CBCETPALOX15ALOX12ENTPD5
SCHEMBL10101139 0.77 PIK3CB (0.38) PIK3CBCETPALOX15ALOX12ENTPD5
SCHEMBL10101208 0.76 PIK3CB (0.43) PIK3CBCETPALOX15ALOX12ENTPD5
SCHEMBL10101134 0.76 PIK3CB (0.43) PIK3CBCETPALOX15ALOX12ENTPD5
SCHEMBL2035426 0.75 POLA1 (0.42) PIK3CBALOX15ALOX12ENTPD5ALDH1A1
SCHEMBL10101257 0.74 POLA1 (0.44) PIK3CBALOX15ALOX12ENTPD5PIK3CA
SCHEMBL10101267 0.73 PIK3CB (0.37) PIK3CBALOX15ALOX12ENTPD5PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1D, PTPRO, PPM1G PIK3CB 98/4885CETP 2346/4885ALOX15 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.